We reported that brain (pro)renin receptor (PRR) expression levels are elevated in DOCA-salt-induced hypertension; however, the underlying mechanism remained unknown. To address whether ANG II type 1 receptor (AT 1R) signaling is involved in this regulation, we implanted a DOCA pellet and supplied 0.9% saline as the drinking solution to C57BL/6J mice. Sham pellet-implanted mice that were provided regular drinking water served as controls. Concurrently, mice were intracerebroventricularly infused with the AT 1R blocker losartan, angiotensin-converting-enzyme inhibitor captopril, or artificial cerebrospinal fluid for 3 wk. Intracerebroventricular infusion of losartan or captopril attenuated DOCA-salt-induced PRR mRNA elevation in the paraventricular nucleus of the hypothalamus, suggesting a role for ANG II/AT 1R signaling in regulating PRR expression during DOCAsalt hypertension. To test which ANG II/AT 1R downstream transcription factors were involved in PRR regulation, we treated Neuro-2A cells with ANG II with or without CREB (cAMP response elementbinding protein) or AP-1 (activator protein-1) inhibitors, or CREB siRNA. CREB and AP-1 inhibitors, as well as CREB knockdown abolished ANG II-induced increases in PRR levels. ANG II also induced PRR upregulation in primary cultured neurons. Chromatin immunoprecipitation assays revealed that ANG II treatment increased CREB binding to the endogenous PRR promoter in both cultured neurons and hypothalamic tissues of DOCA-salt hypertensive mice. This increase in CREB activity was reversed by AT 1R blockade. Collectively, these findings indicate that ANG II acts via AT 1R to upregulate PRR expression both in cultured cells and in DOCA-salt hypertensive mice by increasing CREB binding to the PRR promoter.
THE BRAIN RENIN-ANGIOTENSIN system (RAS) plays an essential role in neurogenic hypertension (4, 21) . The (pro)renin receptor (PRR) is a newly discovered component of the RAS that is highly expressed in the brain (16, 26) . Binding of renin to the PRR increases the catalytic activity of renin by approximately fourfold to fivefold. Prorenin also gains enzymatic activity by binding to the PRR (24) . Binding of renin or prorenin to the PRR also directly initiates an intracellular signaling pathway independent of ANG II that increases the synthesis of profibrotic molecules, including plasminogen activator inhibitor-1, fibronectin, collagen, and transforming growth factor-␤ (10, 25, 26) .
We and others have reported that the PRR is upregulated in the central nervous system (CNS) in different hypertensive models, including spontaneously hypertensive rats (SHR) (27) and human renin-angiotensinogen (RA) double-transgenic hypertensive mice (16) . Knocking down PRR in the brain through virus-mediated introduction of small hairpin (inhibitory) RNA against the PRR (PRR-shRNA) attenuates hypertension in both SHR and RA mice. We also recently reported that PRR expression levels are elevated throughout the brain during DOCA salt-induced hypertension (17) , and neuron-specific PRR deletion prevents the development of DOCA-salt hypertension. Taken together, these reports suggest that the PRR plays a pivotal role in the central regulation of blood pressure. However, it is still not clear how the PRR is upregulated in hypertension.
A common mechanism among these hypertensive animal models is activation of the brain RAS and increased ANG II formation. Here, we report that ANG II acts through the type 1 angiotensin receptor (AT 1 R) to increase PRR expression in the CNS during DOCA-salt hypertension. We also demonstrate that cAMP response element-binding protein (CREB) acts downstream of ANG II/AT 1 R signaling to mediate the increase in PRR expression in response to DOCA-salt by binding to sites identified in the promoter region of the PRR gene (Atp6ip2).
METHODS

Animals.
All animal procedures were approved by the Institutional Animal Care and Use Committee of Colorado State University and were performed in accordance with the "National Institutes of Health Guide to the Care and Use of Experimental Animals". Wild-type C57BL/6J mice were from the Jackson Laboratory (Bar Harbor, ME).
Cell culture and ANG II treatment. Mouse Neuro-2A cells (American Type Culture Collection, Manassas, VA) were plated at a density of 1 ϫ 10 5 cells/ml in DMEM (Invitrogen, Gaithersburg, MD) containing 10% FBS (25) . A consistent passage (P3-P6 from the initially cryopreserved cells) of Neuro-2A cells was used throughout. In ANG II stimulation studies, cells were starved by incubating overnight in serum-free medium followed by treatment with ANG II (100 nM) for different durations (see RESULTS) , with or without the AT 1R blocker losartan (10 M; Sigma-Aldrich, St. Louis, MO), the activator protein-1 (AP-1) inhibitor SR-11302 (5) (10 M; Santa Cruz Biotechnology, Dallas, TX), the CREB-CBP interaction inhibitor CAS92-78-4 (1, 15) (10 M; EMD Millipore, Billerica, MA), or the NF-B inhibitor parthenolide (10 M; EMD Millipore) for 2 h. All inhibitors were added 30 min before ANG II stimulation. After treatment, cells were harvested and used for RT-PCR, Western blotting, and chromatin immunoprecipitation (ChIP) assays. n values represent the number of separate experiments; within an experiment, triplicate determinations were performed for each group.
DOCA-salt hypertension model and intracerebroventricular infusion.
C57BL/6 mice were anesthetized by isoflurane inhalation (3% for induction and 1.5% for maintenance) and then subcutaneously implanted with a 50-mg pellet of DOCA (17) or a sham pellet. After recovery from anesthesia, animals were housed singly in standard forced-air shoebox cages. Control animals were maintained on standard chow and provided ad libitum access to tap water. DOCA animals were maintained on standard chow and provided ad libitum access to a 0.15 M (0.9%) sodium chloride solution.
In protocol 1, losartan (3 mg·kg Ϫ1 ·day Ϫ1 ), captopril (3 mg·kg Ϫ1 · day Ϫ1 ), or artificial cerebrospinal fluid (aCSF) was intracerebroventricularly infused into the lateral cerebroventricle (0.11 l/h) concurrently with DOCA-salt treatment using implanted osmotic minipumps (Alzet, Cupertino, CA) connected to the intracerebroventricular cannula (coordinates: 0.3 mm posterior and 1 mm lateral to bregma and a depth of 3 mm) (17) . Blood pressure in captopril-and aCSF-treated groups was continuously recorded during DOCA-salt treatment using radio telemetry. At the end of the protocol, brains were harvested and immediately frozen in OCT (optimum cutting temperature) compound on dry ice. Paraventricular nuclei (PVN) were micropunched in a cryostat using a brain punch kit (0.75-mm diameter with a depth of 1 mm; Stoelting, Wood Dale, IL) (11) and used for PRR mRNA measurement.
In protocol 2, mice were intracerebroventricularly infused with losartan (3 mg·kg Ϫ1 ·day Ϫ1 ), the CREB-CBP interaction inhibitor CAS92-78-4 (100 M, 0.11 l/h), or aCSF concurrently with DOCAsalt or sham treatment. For ChIP assays, the hypothalamus was dissected. For PRR mRNA measurements, the PVN was micropunched as described above.
Primary neuron culture. Neurons were isolated and cultured from postnatal day 0 (P0) to P2 C57BL/6 mouse pups, as previously described (23) , with slight modifications. Briefly, pups were anesthetized with isoflurane and euthanized by decapitation. Whole brains were rapidly dissected under a stereomicroscope (Olympus, Lake Success, NY) in isolation medium consisting of Neurobasal Medium (Life Technologies, Carlsbad, CA) supplemented with 0.002 mg/ml penicillin/streptomycin and 0.004 mg/ml neomycin. Tissue was digested with dispase (1.5 U/ml; Sigma-Aldrich) and stirred with fresh dispase medium for 10 min; the medium was collected, and the process was repeated for a total of four extractions. Extracted cell supernatants were kept on ice and pooled at the end of tissue digestions. Cells were seeded on poly-D-lysine-coated 25-mm coverslips or 6-well culture plates at a density of 3 ϫ 10 5 cells per coverslip or well. Neuronal cultures were grown/maintained in neurobasal media supplemented with 2% B-27 (Life Technologies) and 5 mM Glutamax-1 (Life Technologies) at 37°C in a humidified 5% CO2 environment for at least 1 wk prior to further experiments. n values represent the number of separate experiments; within an experiment, triplicate determinations were performed for each group.
Immunostaining of primary cultured neurons. Primary neurons on glass coverslips were fixed with methanol for 20 min at Ϫ20°C. After fixation, coverslips were washed three times for 5 min each in 1ϫ Tris-buffered saline (TBS), then incubated in blocking buffer (1% donkey/goat serum in 1ϫ TBS) for 1 h at room temperature. Rabbit anti-MAP2 primary antibody (1:500 in blocking buffer; Abcam, Cambridge, UK) was then added to coverslips and incubated overnight at 4°C. On the next day, coverslips were washed three times for 5 min each in 1ϫ TBS before incubating with anti-rabbit Alexa Fluor 555-conjugated secondary antibody (1:500; Life Technologies) at room temperature for 1 h. Coverslips were washed three more times for 5 min each in 1ϫ TBS and then mounted on glass slides with Vectashield mounting medium containing 4=,6-diamidino-2-phenylindole (DAPI; Vector, Burlingame, CA) and stored at 4°C until used for imaging.
siRNA-mediated CREB knockdown. Neuro-2A cells were plated in six-well culture plates and cultured for 24 h. For transfection, the culture medium was removed, and cells were washed with 2 ml of siRNA transfection medium (Santa Cruz Biotechnology, Dallas, TX). Cells were then incubated with 0.8 ml of transfection mixture composed of CREB siRNA (Santa Cruz Biotechnology) and siRNA transfection reagent (Santa Cruz Biotechnology) for 6 h at 37°C in a CO2 incubator. Normal growth medium (1 ml) was then added to the wells and cells were cultured for an additional 24 h. Thereafter, the medium was replaced with fresh normal growth medium, and cells were cultured for 48 h before further experiments. Scrambled siRNA from the same vendor was used as a negative control. CREB knockdown efficiency was evaluated by assessing total CREB and phosphorylated CREB levels by Western blot analysis (see below).
RNA isolation and real-time RT-PCR. Total RNA from brain tissue or cell cultures was isolated using a standard RNA extraction procedure (RNeasy mini kit; Qiagen Technologies, Hilden, Germany) and quantified using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA). cDNA was synthesized from 200 ng of total RNA using a reverse transcription kit (Applied Biosystems, Foster City, CA). Specific primers for mouse PRR (16) were designed using PrimerQuest Software (Integrated DNA Technologies, Coralville, IA). Real-time RT-PCR was performed on an Mx3000P System (Stratagene, La Jolla, CA) using the SYBR Green qPCR master mix (USB, Cleveland, OH), according to the manufacturers' instructions. Cycling conditions were 95°C for 10 min followed by 40 cycles of 95°C for 15 s, 60°C for 60 s, and 72°C for 30 s. Relative expression was calculated according to the 2 Ϫ⌬⌬CT method (20) using MxPro software. Values were expressed as a ratio relative to control groups. The expression levels of targeted mRNAs were normalized to the expression levels of GAPDH mRNA.
Western blot analysis. Brain tissues and cell cultures were harvested in lysis buffer (Thermo Scientific) containing a protease inhibitor cocktail (Sigma-Aldrich) and homogenized with a glass pestle. The lysate was centrifuged at 13,000 rpm for 10 min, and the supernatant was transferred to a clean tube. Protein concentration was measured using a BCA assay kit (Thermo Scientific). Lysate samples containing equal amounts of protein (25 g) were mixed with SDS-PAGE sample buffer (Invitrogen), heated at 70°C for 10 min, and electrophoresed on a 4 -20% Tris-glycine gel (Invitrogen). After transferring proteins to nitrocellulose membranes using an iBlot gel transfer device (Invitrogen), membranes were blocked by incubating with 5% nonfat milk in PBS containing 0.1% Tween-20 (PBS-T) for 2 h at room temperature, and then incubated overnight at 4°C with an antibody against phosphorylated CREB (P-CREB, phosphorylated at Ser-133, 1:1,000; Cell Signaling Technology, Danvers, MA), total CREB (T-CREB, 1:1,000; Cell Signaling Technology), phosphorylated c-Jun (P-c-Jun, phosphorylated at Ser-63, 1:500; Santa Cruz Biotechnology), total c-Jun (T-c-Jun, 1:500; Santa Cruz Biotechnology), or PRR (1:500) (16) . Membranes were then incubated with peroxidase-conjugated goat anti-rabbit IgG antibody (1:10,000; Jackson Immunoresearch Laboratories, West Grove, PA) for 1 h at room temperature. Immunoreactive protein bands were detected with a UVP Bio-imaging System. After stripping the antibodies by incubating with Western Blot stripping buffer (Thermo Scientific) for 15 min at room temperature, blots were incubated with rabbit anti-mouse ␤-actin antibody (1:1,000; Sigma-Aldrich) for 1 h at room temperature, followed by incubation with peroxidase-conjugated goat anti-rabbit IgG antibody (1:10,000) for 1 h at room temperature. Proteins in blots were again visualized using the UVP Bio-imaging System. Target proteins and ␤-actin were quantified by a separate investigator, blinded to group-identifying information, using the National Institutes of Health's ImageJ software. The expression levels of targeted proteins were normalized to the expression levels of ␤-actin protein.
ChIP assay. Hypothalami from mice that had received 3-wk sham or DOCA-salt treatment (with intracerebroventricular infusion of aCSF or losartan) and Neuro-2A cells (with or without ANG II treatment) were fixed with 1% formaldehyde. ChIP assays were subsequently performed according to the manufacturer's instructions (EMD Millipore). Briefly, chromatin was isolated and sheared by sonicating nine times for 10 s each. The sheared chromatin was immunoprecipitated with anti-P-CREB [5 g/immunoprecipitate (IP)] or anti-P-c-Jun (5 g/IP) antibody overnight at 4°C. Normal mouse IgG (2 g/IP) was used as a negative control, and anti-RNA polymerase II (2 g/IP) antibody was used as a positive control. Nonprecipitated chromatin served as input. After eluting protein/DNA complexes, DNA was purified by removing the antibodies. Input, immunoprecipitate, and negative and positive control fractions were subsequently analyzed by real-time PCR using SYBR Green quantitative PCR master mix (USB). Primer pairs designed to amplify appropriate fragments of the promoter region of the PRR gene are listed in Fig. 4A Bonferroni post hoc tests to compare replicate means. Statistical comparisons were performed using Prism5 (GraphPad Software, La Jolla, CA). Differences were considered statistically significant at P Ͻ 0.05.
RESULTS
DOCA-salt increases brain PRR expression in an ANG
II-dependent manner. We recently reported that PRR levels are significantly upregulated during DOCA-salt-induced hypertension, and showed that chronic intracerebroventricular infusion of losartan prevents the development of DOCA-salt hypertension (17) . To address whether ANG II acts through AT 1 R to participate in the upregulation of PRR in the PVN of the hypothalamus during DOCA-salt hypertension, we first assessed PRR mRNA levels in the PVN following DOCA-salt treatment. PRR mRNA levels trended higher on day 1 (fold change relative to control: 1.18 Ϯ 0.02) after DOCA-salt treatment and were significantly elevated on day 3 (1.49 Ϯ 0.11), day 7 (1.83 Ϯ 0.13), and day 21 (2.56 Ϯ 0.2) (Fig. 1A) . Chronic intracerebroventricular infusion of losartan or captopril for 21 days prevented the DOCA-salt-induced upregulation of PRR mRNA (Fig. 1B) without affecting PRR mRNA levels in sham animals, confirming the involvement of ANG II/AT 1 R signaling. Consistent with this, intracerebroventricular infusion of captopril prevented the development of DOCA-salt hypertension (Fig. 1C) , recorded by telemetry. PRR protein levels were also significantly elevated after 21 days of DOCA-salt treatment (Fig. 1D) .
Involvement of AP-1 and CREB in ANG II-induced PRR upregulation in Neuro-2A cells.
To gain insight into the molecular mechanism by which ANG II regulates PRR expression, we performed a transcription factor prediction search (TFSEARCH ver.1.3). This analysis revealed the presence of Fig. 2A) . We then tested which of these ANG II/AT 1 R downstream transcription factors were involved in PRR regulation. The CREB inhibitor CAS92-78-4 prevented ANG II-induced PRR mRNA upregulation in Neuro-2A cells (Fig. 2B) without affecting PRR mRNA levels in the control group. Similarly, the AP-1 inhibitor SR-11302 also prevented ANG II-induced PRR mRNA upregulation (Fig. 2C) and, like CAS92-78-4, had no effect on PRR expression in control cells. In contrast, NF-B inhibition (parthenolide) had no effect on PRR expression in either control or ANG II-treated cells (Fig. 2D) . Figure 3A shows a representative Western blot and quantification for P-CREB, T-CREB, and ␤-actin in Neuro-2A cells after transfection with scrambled siRNA or CREB siRNA. CREB siRNA decreased both P-CREB and T-CREB levels compared with scrambled siRNA. ANG II induced a time-dependent increase in PRR protein levels, with a significant increase observed 4 h after stimulation (Fig. 3B) . CREB siRNA did not change PRR protein levels in the controls. Importantly, CREB knockdown prevented ANG II-induced (4 h) PRR protein upregulation (Fig. 3C) . Similarly, CREB knockdown prevented ANG II-induced PRR mRNA upregulation (Fig. 4C) .
CREB knockdown prevents ANG II-induced PRR upregulation in Neuro-2A cells.
ANG II increases PRR expression in primary cultured neurons. The Neuro-2A cell line is derived from a mouse neuroblastoma obtained from the hypothalamic brain region. To confirm ANG II effects on PRR regulation in primary neurons, we isolated and cultured mouse brain neurons. Figure  4A1 shows a merged differential interference contrast (DIC, gray) image and DAPI (cyan)-counterstained image of primary neurons; Fig. 4A2 shows an image of immunostaining with the neuronal marker MAP2 (red); and Fig. 4A3 shows a merged image of MAP2, DAPI, and DIC (ϫ64 magnification). ANG II increased PRR mRNA levels as early as 1 h after stimulation (Fig. 4B) and increased PRR protein expression starting 4 h after stimulation (Fig. 4C) . Neuro-2A cells. Fig. 5A shows a representative Western blot for P-CREB (phosphorylated at Ser-133), T-CREB, and ␤-actin in Neuro-2A cells at different time points after stimulation with ANG II. Densitometric quantification of blots showed that ANG II significantly increased CREB phosphorylation at Ser-133 in a time-dependent manner, with the maximal increase observed 60 min after ANG II treatment (Fig. 5B) . Losartan prevented the ANG II-induced increase in CREB phosphorylation, restoring P-CREB to control levels. ANG II had no effect on T-CREB expression within 2 h of incubation (Fig. 5C ). Fig. 5D shows a representative Western blot for P-c-Jun (phosphorylated at Ser-63), T-c-Jun, and ␤-actin at different time points after ANG II stimulation. Quantification of blots showed that ANG II increased c-Jun phosphorylation in a time-dependent manner, with the maximal increase observed 60 min after ANG II stimulation (Fig.  5E) . As was the case for P-CREB, losartan treatment completely prevented the ANG II-induced increase in c-Jun phosphorylation. ANG II had no effect on T-c-Jun expression within 2 h of incubation (Fig. 5F) .
ANG II induces a time-dependent increase in CREB and c-jun phosphorylation in
ANG II increases CREB binding to the endogenous PRR promoter in Neuro-2A cells. Six pairs of primers targeting the PRR promoter were designed, covering a 1,042-base-pair (bp) region upstream of the starting codon (Fig. 6A) . Oligonucleo- Fig. 2 . Inhibition of AT1R, AP-1, or CREB prevents ANG II-induced increases in PRR mRNA levels in Neuro-2A cells. A: PRR mRNA levels in Neuro-2A cells incubated with or without (control) ANG II (100 nM, 1 h) in the presence or absence of losartan (10 M) for 2 h (n ϭ 4 in control and ANG II groups; n ϭ 3 in control ϩ losartan group and ANG II ϩ losartan group). B: PRR mRNA levels in control, control ϩ CREB inhibitor (CAS92-78-4; 10 M), ANG II (100 nM, 1 h), and ANG II ϩ CAS92-78-4 (n ϭ 3) groups. C: PRR mRNA levels in control, control ϩ AP-1 inhibitor (SR11302; 10 M), ANG II (100 nM, 1 h), and ANG II ϩ SR11302 (n ϭ 3) groups. D: PRR mRNA levels in control, control ϩ NF-B inhibitor (parthenolid; 10 M), ANG II (100 nM, 1 h), and ANG II ϩ parthenolid (n ϭ 3) groups. n values represent the number of separate experiments; within an experiment; triplicate determinations were performed for each group (*P Ͻ 0.05 vs. control. #P Ͻ 0.05 vs. ANG II).
tide sequences are presented in Table 1 . To detect P-CREB and P-c-Jun binding to different regions of the endogenous PRR promoter in response to ANG II treatment in Neuro-2A cells, we performed ChIP assays. P-CREB binding activity in the Ϫ270/Ϫ39 bp promoter region, detected by primer 6, was increased in ANG II-treated cells compared with controls (Fig.  6B) . A CREB-binding sequence (TGACGTCG) that is highly conserved compared with the consensus CRE sequence (TGACGTCA) was identified at Ϫ212/Ϫ205 within this region. No increased P-c-Jun binding at the PRR promoter was detected, although decreased binding activity was detected by primers 1 and 2 following ANG II treatment (Fig. 6C) .
Increases in CREB phosphorylation and CREB binding to the endogenous PRR promoter in the hypothalamus of DOCAsalt hypertensive mice. Figure 7A shows a representative Western blot for P-CREB, T-CREB, and ␤-actin in the mouse hypothalamus in sham, sham with intracerebroventricular infusion of losartan, DOCA-salt with intracerebroventricular A2), and merged image of MAP2, DAPI, and DIC (ϫ64 magnification) (A3). B: PRR mRNA levels in controls and animals treated with ANG II (100 nM) for 1, 2, or 4 h (n ϭ 3; *P Ͻ 0.05 vs. control). C: representative Western blots for PRR and ␤-actin and quantification of PRR protein expression in primary cultured neurons treated with ANG II (100 nM) for 2, 4, or 6 h (n ϭ 3; *P Ͻ 0.05 vs. control). n values represent the number of separate experiments; within an experiment, duplicate (for protein) or triplicate (for mRNA) determinations were performed for each group. infusion of aCSF, and DOCA-salt with intracerebroventricular infusion of losartan conditions. Twenty-one days of DOCAsalt treatment significantly increased CREB phosphorylation in the hypothalamus. Chronic intracerebroventricular infusion of losartan prevented the DOCA-salt-induced increase in CREB phosphorylation ( Figure 7B ). However, neither DOCA-salt nor chronic intracerebroventricular infusion of losartan affected T-CREB levels (Fig. 7C) . Furthermore, P-CREB binding to the PRR promoter detected by primer 6 was significantly increased following 3 wk of DOCA-salt treatment (Fig. 8A) . Notably, intracerebroventricular infusion of losartan completely prevented the DOCA-salt-induced increase in P-CREB binding to the endogenous PRR promoter in the hypothalamus. Importantly, intracerebroventricular infusion of the CREB inhibitor CAS92-78-4 completely prevented DOCA-salt-induced PRR mRNA upregulation in the PVN (Fig. 8B) .
DISCUSSION
The PRR plays a pivotal role in brain ANG II formation and the central regulation of blood pressure (17, 18) . However, our understanding of the factors that influence the expression of this receptor in the CNS is still evolving. In the present study, we sought to identify ANG II signaling pathways involved in regulating PRR expression. We found that ANG II upregulated PRR expression in neuronal cells and primary cultured neurons and showed that pharmacological intervention of AP-1 and CREB signaling pathways blocked ANG II-induced PRR expression. Furthermore, we showed that AT 1 R or CREB blockade prevented DOCA-salt-induced PRR upregulation in the brain and identified the functional binding sites of CREB on the promoter region of the PRR. Finally, we demonstrated that CREB binding to the endogenous PRR promoter was elevated in the hypothalamus of DOCA-salt hypertensive mice, and this increase was reversed by AT 1 R blockade.
The first important finding in this study is that ANG II increased PRR expression in Neuro-2A cells, an effect that was blocked by losartan. ANG II is the major bioactive member of the RAS, and overactivity of the RAS in the CNS is a hallmark of several disease states characterized by sympathoexcitation, such as hypertension. ANG II is known to activate numerous transcription factors, including AP-1 (2) and CREB (6, 7) . It has been reported that ANG II increases phosphorylation of c-Fos and c-Jun, two components of AP-1, in the rostral ventrolateral medulla, a major sympathetic control center of the brain (19) . Phosphorylation of CREB is important for the regulation of gene expression and hypertrophy of vascular smooth muscle cells by ANG II (6) . ANG II-induced CREB phosphorylation is mediated by at least three distinct pathways (6): 1) an ERK pathway that can be blocked by the ERK inhibitor PD98059, 2) a p38 MAPK pathway that can be blocked by the P38 inhibitor SB203580, and 3) a PKAdependent pathway that can be blocked by the PKA inhibitor H89. Phosphorylation of CREB at Ser-133 results in recruitment of the transcriptional coactivator, CREB-binding protein (CBP), which is essential for transcriptional activation (3). Our results are in agreement with previous reports that ANG II activates CREB through phosphorylation at Ser-133 and induces AP-1 activity through phosphorylation of c-Jun, as well as with reports that losartan blocks ANG II-induced CREB and c-Jun phosphorylation (2, 7) . A new finding in this study is that inhibition of CREB-CBP prevents ANG II-induced PRR upregulation in cultured Neuro-2A cells. We also found that CREB phosphorylation and PRR expression were increased in the mouse hypothalamus during DOCA-salt hypertension, and this increase was prevented by intracerebroventricular infusion of losartan, suggesting a role for ANG II in CREB phosphorylation and PRR upregulation in this hypertensive model.
The fact that inhibition of CREB-CBP or AP-1 prevented ANG II-induced PRR upregulation suggested that these transcription factors might directly regulate PRR transcription through binding to elements in the PRR promoter. ChIP assays performed in vitro to identify potential binding sites on the PRR promoter revealed that CREB binding activity increase in the Ϫ270/Ϫ39 region of the PRR promoter after ANG II treatment. Surprisingly, these assays showed no increase, but rather a small decrease, in c-Jun binding to the PRR promoter. The physiological significance of this decrease in P-c-Jun binding is not clear at this time, but it is an issue that we plan to address at some point in the future. Our data showed that although ANG II phosphorylates c-Jun, P-c-Jun binding to the PRR promoter was not elevated, suggesting that at least within the region of the PRR promoter tested, AP-1 does not contribute to ANG II-induced upregulation of PRR expression. Instead, a reduction in P-c-Jun binding might be a compensatory mechanism for PRR upregulation induced by other mechanisms, such as the CREB pathway. It is also possible that other P-c-Jun-binding sites lying outside the tested 1,042-bp upstream region of the PRR promoter may participate in PRR regulation, a question we plan to investigate in our future study. In addition, increasing evidence suggests that transcription factors function collectively in a regulated network to ultimately affect cell signaling (7, 14) , providing a possible alternative explanation for decrease in P-c-Jun binding on PRR promoter regions. We tested as well the effect of AP-1 inhibitor on PRR mRNA levels. For example, crosstalk between CREB and c-Fos/c-Jun confers both gain and loss of function in the fine-tuning of regulatory events involved in transcription (22) . In our case, AP-1 inhibition might interrupt CREB binding to the PRR promoter in response to ANG II and, in turn, prevent the ANG II-induced increase in PRR expression. In the hypothalamus of DOCA-salt hypertensive mice, CREB binding activity at the Ϫ270/Ϫ39 region of the endogenous PRR promoter was markedly increased, and intracerebroventricular infusion of losartan or CREB inhibitor prevented this increase, suggesting that the CREB mechanism observed in vitro also operates in vivo.
We previously reported that PRR expression was only increased 1.2-to 1.5-fold, depending on the brain area, in human RA double-transgenic mice (16) . In this mouse model, the major phenotype is chronic hypertension accompanied by high plasma and tissue ANG II levels, suggesting that the increase in PRR expression may be caused by high levels of ANG II. It has also previously been shown that PRR expression is increased 1.3-to 1.7-fold in different brain regions in the SHR model (27) . Although the authors of this latter study did not elucidate the mechanism of PRR upregulation, hyperactivity of the brain RAS is known to play a critical role in the development of hypertension in the SHR model (8) and might contribute to PRR regulation. In our in vitro study, ANG II induced a 1.4-fold increase in PRR mRNA levels and about a twofold increase in PRR protein levels; it also increased CREB binding activity by 1.6-fold. Interestingly, DOCA-salt induced a 2.6-fold increase in PRR expression and about a fourfold increase in CREB binding activity. The fact that intracerebroventricular infusion of losartan prevented both DOCA-salt-induced PRR upregulation and increased CREB binding activity suggests the importance of ANG II/AT 1 R signaling in the regulation of PRR in DOCA-salt hypertension, but begs the question: why is the increase in PRR expression and CREB binding much more dramatic in the DOCA-salt hypertension model than in a pure ANG II-induced hypertension model? A recent study showed that, during DOCA-salt hypertension, histone deacetylase (HDAC) activity is increased in association with upregulation of cardiac hypertrophic markers (13) . HDAC catalyzes the removal of acetyl groups from histone residues and plays a key role in epigenetic regulation of histone and nonhistone proteins. It has also been shown that HDAC inhibition suppresses the expression of inflammatory cytokines during DOCA-salt hypertension (12) , suggesting a role for HDAC in regulating the expression of inflammatory cytokines. Collectively, these reports suggest the possibility that other mechanisms (e.g., epigenetic regulation) could facilitate the recruitment of additional transcription factors, such as CREB, to the PRR promoter region and, thus, induce higher levels of PRR expression. Additional studies will be needed to confirm this supposition.
Interestingly, a previous report showed that renal PRR expression is also upregulated in the streptozotocin-induced diabetic rat model, and that AT 1 R blockade inhibits this upregulation (28), suggesting a role for ANG II in upregulation of renal PRR during diabetes. Huang and Siragy (9) reported that sodium depletion significantly upregulates PRR mRNA and protein expression in the rat kidney. Although the authors did not demonstrate a direct relationship between ANG II and PRR upregulation in this model, it is well known that sodium depletion increases renal renin synthesis (29) and activates the systemic RAS. In the present study, we found that ANG II directly increased PRR expression in the CNS through increased CREB binding to the PRR promoter. Activation of prorenin by the PRR is one of the major mechanisms for producing ANG II in the brain (17) , suggesting the existence of a positive feedback system for PRR upregulation in the CNS.
In summary, our study indicates that ANG II acts via AT 1 R to upregulate PRR expression in both cultured cells and DOCA-salt hypertension by increasing CREB binding to the PRR promoter. The positive feedback between ANG II and the PRR may be a key contributor to the development of neurogenic hypertension.
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